Status:
RECRUITING
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Lead Sponsor:
Eli Lilly and Company
Conditions:
Osteoarthritis, Knee
Diabetic Neuropathic Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific append...
Detailed Description
The chronic pain master protocol (CPMP) establishes entry criteria and includes DSA for osteoarthritis of the knee, chronic low back pain, and diabetic peripheral neuropathic pain. The DSA have specif...
Eligibility Criteria
Inclusion
- have a visual analog scale (VAS) pain value \>40 and \<95 at screening and prerandomization screening.
- have a history of daily pain for at least 12 weeks based on participant report or medical history
- have a value of ≤30 on the pain catastrophizing scale
- have a body mass index \<40 kilogram/square meter (kg/m²) (inclusive)
- are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.
- are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study
Exclusion
- have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia
- have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)
- have surgery planned during the study for any reason, related or not to the disease state under evaluation.
- have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
- have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.
- have fibromyalgia
- have substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)
- have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.
- have a positive human immunodeficiency virus (HIV) test result at screening
- have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.
Key Trial Info
Start Date :
January 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT05986292
Start Date
January 30 2020
End Date
April 1 2027
Last Update
November 5 2025
Active Locations (64)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Research Associates
Birmingham, Alabama, United States, 35205
2
Simon Williamson Clinic
Birmingham, Alabama, United States, 35211
3
Synexus Clinical Research - Glendale
Glendale, Arizona, United States, 85306
4
Central Phoenix Medical Clinic
Phoenix, Arizona, United States, 85020